A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

Yu Lung Lau, S. J.Rupert Vessey, Ivan S.F. Chan, Tsz Leung Lee, Li Min Huang, Chin Yun Lee, Tzou-Yien Lin, Bee Wah Lee, Kow Kwan, Siti M. Kasim, Christina Y. Chan, Karen M. Kaplan, Daniel J. Distefano, Anna L. Harmon, Amy Golie, Jonathan Hartzel, Jin Xu, Shu Li, Holly Matthews, Jerald C. SadoffAlan Shaw

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

Original languageEnglish
Pages (from-to)2942-2949
Number of pages8
JournalVaccine
Volume20
Issue number23-24
DOIs
Publication statusPublished - Jul 26 2002
Externally publishedYes

Fingerprint

Chickenpox Vaccine
immune response
vaccines
Safety
dosage
Double-Blind Method
Therapeutics

Keywords

  • Immunogenicity
  • Varicella vaccination
  • Varicella zoster virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lau, Y. L., Vessey, S. J. R., Chan, I. S. F., Lee, T. L., Huang, L. M., Lee, C. Y., ... Shaw, A. (2002). A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. Vaccine, 20(23-24), 2942-2949. https://doi.org/10.1016/S0264-410X(02)00245-1

A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. / Lau, Yu Lung; Vessey, S. J.Rupert; Chan, Ivan S.F.; Lee, Tsz Leung; Huang, Li Min; Lee, Chin Yun; Lin, Tzou-Yien; Lee, Bee Wah; Kwan, Kow; Kasim, Siti M.; Chan, Christina Y.; Kaplan, Karen M.; Distefano, Daniel J.; Harmon, Anna L.; Golie, Amy; Hartzel, Jonathan; Xu, Jin; Li, Shu; Matthews, Holly; Sadoff, Jerald C.; Shaw, Alan.

In: Vaccine, Vol. 20, No. 23-24, 26.07.2002, p. 2942-2949.

Research output: Contribution to journalArticle

Lau, YL, Vessey, SJR, Chan, ISF, Lee, TL, Huang, LM, Lee, CY, Lin, T-Y, Lee, BW, Kwan, K, Kasim, SM, Chan, CY, Kaplan, KM, Distefano, DJ, Harmon, AL, Golie, A, Hartzel, J, Xu, J, Li, S, Matthews, H, Sadoff, JC & Shaw, A 2002, 'A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children', Vaccine, vol. 20, no. 23-24, pp. 2942-2949. https://doi.org/10.1016/S0264-410X(02)00245-1
Lau, Yu Lung ; Vessey, S. J.Rupert ; Chan, Ivan S.F. ; Lee, Tsz Leung ; Huang, Li Min ; Lee, Chin Yun ; Lin, Tzou-Yien ; Lee, Bee Wah ; Kwan, Kow ; Kasim, Siti M. ; Chan, Christina Y. ; Kaplan, Karen M. ; Distefano, Daniel J. ; Harmon, Anna L. ; Golie, Amy ; Hartzel, Jonathan ; Xu, Jin ; Li, Shu ; Matthews, Holly ; Sadoff, Jerald C. ; Shaw, Alan. / A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. In: Vaccine. 2002 ; Vol. 20, No. 23-24. pp. 2942-2949.
@article{0d76ad1b239c4f47ab9801485663cabf,
title = "A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children",
abstract = "This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6{\%}, respectively.",
keywords = "Immunogenicity, Varicella vaccination, Varicella zoster virus",
author = "Lau, {Yu Lung} and Vessey, {S. J.Rupert} and Chan, {Ivan S.F.} and Lee, {Tsz Leung} and Huang, {Li Min} and Lee, {Chin Yun} and Tzou-Yien Lin and Lee, {Bee Wah} and Kow Kwan and Kasim, {Siti M.} and Chan, {Christina Y.} and Kaplan, {Karen M.} and Distefano, {Daniel J.} and Harmon, {Anna L.} and Amy Golie and Jonathan Hartzel and Jin Xu and Shu Li and Holly Matthews and Sadoff, {Jerald C.} and Alan Shaw",
year = "2002",
month = "7",
day = "26",
doi = "10.1016/S0264-410X(02)00245-1",
language = "English",
volume = "20",
pages = "2942--2949",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23-24",

}

TY - JOUR

T1 - A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

AU - Lau, Yu Lung

AU - Vessey, S. J.Rupert

AU - Chan, Ivan S.F.

AU - Lee, Tsz Leung

AU - Huang, Li Min

AU - Lee, Chin Yun

AU - Lin, Tzou-Yien

AU - Lee, Bee Wah

AU - Kwan, Kow

AU - Kasim, Siti M.

AU - Chan, Christina Y.

AU - Kaplan, Karen M.

AU - Distefano, Daniel J.

AU - Harmon, Anna L.

AU - Golie, Amy

AU - Hartzel, Jonathan

AU - Xu, Jin

AU - Li, Shu

AU - Matthews, Holly

AU - Sadoff, Jerald C.

AU - Shaw, Alan

PY - 2002/7/26

Y1 - 2002/7/26

N2 - This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

AB - This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.

KW - Immunogenicity

KW - Varicella vaccination

KW - Varicella zoster virus

UR - http://www.scopus.com/inward/record.url?scp=0037178307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037178307&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00245-1

DO - 10.1016/S0264-410X(02)00245-1

M3 - Article

C2 - 12126906

AN - SCOPUS:0037178307

VL - 20

SP - 2942

EP - 2949

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 23-24

ER -